Publicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (10)

2022

  1. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

    eClinicalMedicine, Vol. 50

  2. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

    Trials, Vol. 23, Núm. 1

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2017

  1. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

2016

  1. Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3291-3300

2014

  1. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: A propensity score analysis

    Clinical Infectious Diseases, Vol. 58, Núm. 10, pp. 1413-1421

  2. Validation of a prognostic score for early mortality in severe head injury cases

    Journal of Neurosurgery, Vol. 121, Núm. 6, pp. 1314-1322

2013

  1. Necessary resources and barriers perceived by professionals in the implementation of the NIDCAP

    Early Human Development, Vol. 89, Núm. 9, pp. 649-653

2009

  1. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 5, pp. 751-756

2008

  1. Gestational diabetes mellitus in a cohort of HIV-1 infected women

    HIV Medicine, Vol. 9, Núm. 10, pp. 868-874